Oncopeptides Ab Drug Patent Portfolio
Oncopeptides Ab owns 1 orange book drug protected by 6 US patents Given below is the list of Oncopeptides Ab's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10285946 | Lyophilized preparations of melphalan flufenamide | 25 Apr, 2032 | Active |
| US10322182 | Lyophilized preparation of cytotoxic dipeptides | 25 Apr, 2032 | Active |
| US10543274 | Lyophilized preparation of cytotoxic dipeptides | 25 Apr, 2032 | Active |
| US10869928 | Lyophilized preparation of cytotoxic dipeptides | 25 Apr, 2032 | Active |
| US11344622 | Lyophilized preparation of cytotoxic dipeptides | 25 Apr, 2032 | Active |
| US6992207 | Melphalan derivatives and their use as cancer chemotherapeutic drugs | 25 Jun, 2024 | Expired |
Latest Legal Activities on Oncopeptides Ab's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Oncopeptides Ab.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Interim Patent Term Extension Granted
Critical
| 24 Jun, 2024 | US6992207 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 05 Jun, 2024 | US10869928 |
| Requirement for information sent under 37 CFR 1.750 | 13 May, 2024 | US6992207 |
| Letter from FDA or Dept of Agriculture re PTE application | 18 Apr, 2024 | US6992207 |
|
PTE Interim Patent Extension filed
Critical
| 22 Mar, 2024 | US6992207 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 12 Jul, 2023 | US10543274 |
|
Interim Patent Term Extension Granted
Critical
| 06 Jun, 2023 | US6992207 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 30 Nov, 2022 | US10322182 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 02 Nov, 2022 | US10285946 |
|
Recordation of Patent Grant Mailed
Critical
| 31 May, 2022 | US11344622 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 31 May, 2022 | US11344622 |
|
Interim Patent Term Extension Granted
Critical
| 25 May, 2022 | US6992207 |
|
Email Notification
Critical
| 12 May, 2022 | US11344622 |
|
Issue Notification Mailed
Critical
| 11 May, 2022 | US11344622 |
| Dispatch to FDC | 28 Apr, 2022 | US11344622 |
Oncopeptides Ab's Family Patents
Oncopeptides Ab Drug List
Given below is the complete list of Oncopeptides Ab's drugs and the patents protecting them.
1. Pepaxto
Pepaxto is protected by 6 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10285946 | Lyophilized preparations of melphalan flufenamide |
25 Apr, 2032
(6 years from now)
| Active |
| US10322182 | Lyophilized preparation of cytotoxic dipeptides |
25 Apr, 2032
(6 years from now)
| Active |
| US10543274 | Lyophilized preparation of cytotoxic dipeptides |
25 Apr, 2032
(6 years from now)
| Active |
| US10869928 | Lyophilized preparation of cytotoxic dipeptides |
25 Apr, 2032
(6 years from now)
| Active |
| US11344622 | Lyophilized preparation of cytotoxic dipeptides |
25 Apr, 2032
(6 years from now)
| Active |
| US6992207 | Melphalan derivatives and their use as cancer chemotherapeutic drugs |
25 Jun, 2024
(10 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pepaxto's drug page